前列地尔联合贝前列素钠序贯治疗急性缺血性脑卒中134例临床观察

Sequential therapy of combined alprostadil and beraprost sodium for acute ischemic stroke:clinical observation of 134 cases

目的观察前列地尔联合贝前列素钠序贯治疗急性缺血性脑卒中(AIS)的临床疗效。方法268例AIS患者随机分为对照组和实验组,分别给予常规治疗或加用前列地尔联合贝前列素钠序贯治疗6个月,比较两组凝血功能、肾小球滤过率(GFR)、NIHSS评分、Barthel指数(BI)及复发率。结果实验组GFR、BI明显高于对照组(P<0.01);而NIHSS评分低于对照组(P<0.01);两组凝血功能、复发率差异无统计学意义(P>0.05)。结论前列地尔联合贝前列素钠序贯治疗可改善AIS患者的肾功能和神经功能,且不增加出血风险。

Objective To observe the clinical efficacy of sequential?therapy of combined alprostadil and beraprost sodium (BPS) for acute ischemic stroke (AIS). Methods A total of 268 patients with AIS were randomly divided into control and experimental groups, and respectively treated with routine treatment or routine treatment plus sequential treatment of alprostadil and BPS for 6 months. Coagulation function, glomerular filtration rate (GFR), NIHSS, Barthel index (BI), and recurrence rate were compared between 2 groups. Results Compared with control group, GFR and BI were increased but NIHSS decreased in experimental group (P<0.01). Coagulation function and recurrence rate showed no significant difference between 2 groups (P>0.05). Conclusion Sequential therapy of combined alprostadil and BPS can improve renal and neurological functions without incremental bleeding risk in patients with AIS.